Clinical significance of interleukin-32 expression in patients with rheumatoid arthritis

Asian Pacific Journal of Allergy and Immunology

Volumn 31, Issue 1, 2013, Pages 73-78

  Gui, Ming ^a   Zhang, Hao ^a   Zhong, Kuangbiao ^a   Li, Ying ^a   Sun, Jian ^a   Wang, Li ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

C reactive protein; Connective tissue diseases; Interleukin 32; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

BETA ACTIN; C REACTIVE PROTEIN; COMPLEMENTARY DNA; INTERLEUKIN 32; LEFLUNOMIDE; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DAS28; DERMATOMYOSITIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; HUMANS; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84873556463     PISSN: 0125877X     EISSN: 22288694     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Andersson AK, Li C, Brennan FM. Recent developments in the immunobiology of rheumatoid arthritis. Arthritis ResTher.2008; 10:204.
2. Singh K, Deshpande P, Pryshchep S, Colmegna I, Liarski V, Weyand CM, et al. ERK-dependent T-cell receptor threshold calibration in rheumatoid arthritis. J Immunol. 2009; 183:8258-67.
3. Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther. 2009; 11:R114.
4. Tanaka M, Nagai T, Tsuneyoshi Y, Sunahara N, Matsuda T, Nakamura T, et al. Expansion of a unique macrophage subset in rheumatoid arthritis synovial lining layer. Clin Exp Immunol. 2008; 154:38-47.
5. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010; 233:233-55.
6. Li W, Liu Y, Mukhtar MM, Gong R, Pan Y, Rasool ST, et al. Activation of Interleukin-32 Pro-Inflammatory Pathway in Response to Influenza A Virus Infection. PLoS One. 2008; 3:e1985.
7. Marcondes AM, Ramakrishnan A, Deeg HJ. Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS. Curr Cancer Ther Rev. 2009; 5:310-4.
8. Kobayashi H, Yazlovitskaya EM, Lin PC. Interleukin-32 positively regulates radiation-induced vascular inflammation. Int J Radiat Oncol Biol Phys. 2009; 74:1573-9.
9. Gabay C, McInnes IB. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. Arthritis Res Ther. 2009; 11:230.
10. Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A, et al. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw. 2005; 16:289-92.
11. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA. 2006; 103:3298-303.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31:315-24.
13. Prevoo ML, van Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38:44-8.
14. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343:1594-602.
15. Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, et al. Identification of the most active interleukin-32isoform. Immunology. 2009; 126:535-42.
16. Carter KL, Cahir-McFarland E, Kieff E. Epstein-Barr virus-induced changes n B-lymphocyte gene expression. J Virol. 2002; 76:10427-36.
17. Park GH, Choe J, Choo HJ, Park YG, Sohn J, Kim MK. Genome-wide expression profiling of 8-chloroadenosine-and 8-chloro-cAMP-treated human neuroblastoma cells using radioactive human cDNA microarray. Exp Mol Med. 2002; 34:184-93.
18. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005:22:131-42.
19. Brown J, Matutes E, Singleton A, Price C, Molgaard H, Buttle D, et al. Lymphopain a cytotoxic T and naturalkiller cell-associated cysteine proteinase. Leukemia. 1998; 12:1771-81.